Vitiligo after treatment with Pembrolizumab in a patient with metastatic bronchopulmonary adenocarcinoma : a case report with review of the literature.

Vitiligo has been reported in 2% to 8.3% of patients followed for melanoma. Other studies have reported the rarity of this event, especially in patients followed for other metastatic cancers. We report a rare case of vitiligo which occurred in a 67-year-old patient followed for metastatic bronchopulmonary cancer treated with immunotherapy such as Pembrolizumab. Vitiligo occurring with the use of pembrolizumab in bronchopulmonary cancer has been exceptionally reported in the literature. Immunotherapy in bronchopulmonary cancer is associated with many side effects, vitiligo is very rare in this context and can have an impact on the quality of life of patients.